 Michael Wilson
Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology | 5 | 2016 | 21 | 2.560 |
Why?
| | Global Health | 3 | 2023 | 290 | 1.350 |
Why?
| | Pathology, Clinical | 3 | 2014 | 32 | 1.150 |
Why?
| | Clinical Laboratory Services | 2 | 2018 | 8 | 1.130 |
Why?
| | Clinical Laboratory Techniques | 3 | 2015 | 87 | 0.890 |
Why?
| | Internship and Residency | 3 | 2015 | 951 | 0.740 |
Why?
| | Autopsy | 2 | 2014 | 86 | 0.700 |
Why?
| | Health Equity | 1 | 2019 | 56 | 0.620 |
Why?
| | Early Diagnosis | 1 | 2019 | 220 | 0.610 |
Why?
| | Reimbursement Mechanisms | 2 | 2015 | 78 | 0.590 |
Why?
| | Artificial Intelligence | 1 | 2018 | 148 | 0.580 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 249 | 0.530 |
Why?
| | Calciphylaxis | 1 | 2015 | 2 | 0.520 |
Why?
| | Search Engine | 1 | 2015 | 10 | 0.520 |
Why?
| | Microbiology | 1 | 2015 | 17 | 0.510 |
Why?
| | Health Services Misuse | 1 | 2015 | 36 | 0.490 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 684 | 0.490 |
Why?
| | Malaria, Vivax | 1 | 2014 | 4 | 0.490 |
Why?
| | Antimalarials | 1 | 2014 | 24 | 0.480 |
Why?
| | Malaria, Falciparum | 1 | 2014 | 25 | 0.480 |
Why?
| | Pathology, Molecular | 1 | 2014 | 26 | 0.470 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2015 | 91 | 0.470 |
Why?
| | Efficiency | 1 | 2015 | 84 | 0.470 |
Why?
| | Quality of Health Care | 1 | 2018 | 576 | 0.440 |
Why?
| | Cooperative Behavior | 1 | 2014 | 390 | 0.390 |
Why?
| | Education, Medical | 1 | 2014 | 225 | 0.390 |
Why?
| | Students, Medical | 1 | 2014 | 277 | 0.360 |
Why?
| | Communication | 1 | 2015 | 750 | 0.350 |
Why?
| | Genomics | 1 | 2014 | 645 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2014 | 646 | 0.340 |
Why?
| | Health Personnel | 1 | 2014 | 581 | 0.320 |
Why?
| | Humans | 25 | 2023 | 115587 | 0.290 |
Why?
| | Developing Countries | 2 | 2019 | 240 | 0.280 |
Why?
| | Physicians | 1 | 2015 | 776 | 0.280 |
Why?
| | Urinary Tract Infections | 2 | 2004 | 136 | 0.260 |
Why?
| | Urine | 1 | 2004 | 56 | 0.230 |
Why?
| | Microbiological Techniques | 1 | 2002 | 29 | 0.210 |
Why?
| | Neoplasms | 1 | 2016 | 2118 | 0.200 |
Why?
| | Otitis Media | 1 | 2023 | 142 | 0.190 |
Why?
| | Levamisole | 2 | 2011 | 20 | 0.180 |
Why?
| | Communicable Diseases | 1 | 2002 | 130 | 0.180 |
Why?
| | Urban Population | 2 | 2018 | 405 | 0.170 |
Why?
| | Cocaine | 2 | 2011 | 153 | 0.160 |
Why?
| | Interferon-gamma Release Tests | 1 | 2018 | 26 | 0.150 |
Why?
| | Urban Health Services | 1 | 2018 | 61 | 0.150 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 141 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2018 | 64 | 0.140 |
Why?
| | Clinical Audit | 1 | 2015 | 11 | 0.130 |
Why?
| | Cost Control | 1 | 2015 | 40 | 0.130 |
Why?
| | Utilization Review | 1 | 2015 | 34 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1086 | 0.130 |
Why?
| | Population Surveillance | 1 | 2018 | 395 | 0.120 |
Why?
| | Health Education | 1 | 2018 | 325 | 0.120 |
Why?
| | Benchmarking | 1 | 2016 | 163 | 0.120 |
Why?
| | Drug Contamination | 2 | 2011 | 53 | 0.120 |
Why?
| | Agranulocytosis | 2 | 2011 | 31 | 0.110 |
Why?
| | Public Health | 1 | 2018 | 438 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2004 | 299 | 0.100 |
Why?
| | Mass Screening | 1 | 2018 | 1024 | 0.100 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2011 | 54 | 0.090 |
Why?
| | Escherichia coli | 2 | 2004 | 730 | 0.090 |
Why?
| | Cocaine-Related Disorders | 1 | 2011 | 107 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 206 | 0.090 |
Why?
| | Primary Health Care | 1 | 2018 | 1518 | 0.080 |
Why?
| | Quality Improvement | 1 | 2015 | 958 | 0.070 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 41 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2004 | 33 | 0.060 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2003 | 13 | 0.060 |
Why?
| | Bronchopneumonia | 1 | 2003 | 5 | 0.060 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2003 | 39 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 50 | 0.060 |
Why?
| | Hospitals, Public | 1 | 2003 | 23 | 0.060 |
Why?
| | Nasopharynx | 1 | 2023 | 63 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 45 | 0.050 |
Why?
| | Chorioamnionitis | 1 | 2003 | 36 | 0.050 |
Why?
| | Escherichia coli Infections | 1 | 2003 | 102 | 0.050 |
Why?
| | Mycoses | 1 | 2003 | 67 | 0.050 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 61 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 133 | 0.050 |
Why?
| | Fetal Diseases | 1 | 2003 | 148 | 0.050 |
Why?
| | Bacterial Infections | 1 | 2003 | 222 | 0.050 |
Why?
| | Virus Diseases | 1 | 2003 | 200 | 0.050 |
Why?
| | Acute Disease | 1 | 2023 | 914 | 0.050 |
Why?
| | Tuberculin Test | 1 | 2018 | 32 | 0.040 |
Why?
| | Female | 4 | 2018 | 59913 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 278 | 0.040 |
Why?
| | Bacteria | 1 | 2023 | 729 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2018 | 12608 | 0.030 |
Why?
| | Adult | 4 | 2010 | 30718 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2800 | 0.030 |
Why?
| | Male | 4 | 2018 | 55949 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1484 | 0.030 |
Why?
| | Child | 3 | 2023 | 18488 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4113 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2003 | 5077 | 0.030 |
Why?
| | Pregnancy | 1 | 2003 | 5548 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 50 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 21 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3022 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 125 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 97 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 129 | 0.020 |
Why?
| | Crack Cocaine | 1 | 2010 | 8 | 0.020 |
Why?
| | Leukopenia | 1 | 2010 | 27 | 0.020 |
Why?
| | Infant | 1 | 2023 | 7979 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 294 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 127 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4440 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 8697 | 0.020 |
Why?
| | Child, Preschool | 2 | 2018 | 9133 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 249 | 0.020 |
Why?
| | Prevalence | 1 | 2011 | 2264 | 0.020 |
Why?
| | Adolescent | 2 | 2018 | 17889 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2003 | 66 | 0.010 |
Why?
| | Drug Resistance, Bacterial | 1 | 2003 | 156 | 0.010 |
Why?
| | Community-Acquired Infections | 1 | 2003 | 140 | 0.010 |
Why?
| | Prospective Studies | 1 | 2003 | 6264 | 0.010 |
Why?
| | Middle Aged | 1 | 2003 | 26999 | 0.000 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|